

## Fisher, Alexander

---

**From:** Emily Haugh <emily@realsolutionsgroup.co>  
**Sent:** Wednesday, December 4, 2024 1:51 PM  
**To:** Fisher, Alexander  
**Subject:** Upcoming letter regarding illegal GLP-1 Compounding in New Hampshire

**EXTERNAL: Do not open attachments or click on links unless you recognize and trust the sender.**

---

Good afternoon Mr. Fisher,

I am writing to share some concerning updates on the topic of GLP-1 compounding and to offer support to Board staff. This issue has been developing over the past several weeks since FDA has removed tirzepatide from the shortage list. Since FDA's announcement, there has been an increase in compounding activity that circumvents FDA shortage requirements, including the marketing of oral formulations that lack efficacy (due to very low bioavailability), encouraging patients to stockpile tirzepatide, and introducing new injectable formulations that contain vitamin additives. There are also serious concerns around lack of sterility of these products.

We have been monitoring this activity and have identified several companies that are marketing and supplying illegally compounded tirzepatide to New Hampshire patients.

Our client Eli Lilly intends to send a letter to the Board outlining these concerns. After you receive the letter, Eli Lilly would greatly appreciate the opportunity to meet with Board staff and discuss the best way such information can be shared with the Board moving forward.

Kind regards,  
Emily Haugh, RPh  
License #4035

--

**EMILY HAUGH** | Associate  
(p) 617-285-0814 (MST/MDT)  
(e) [emily@realsolutionsgroup.co](mailto:emily@realsolutionsgroup.co)

**REAL SOLUTIONS GROUP** | [www.realsolutionsgroup.co](http://www.realsolutionsgroup.co)  
Building a culture of REAL compliance.

*The information provided in this email does not, and is not intended to, constitute legal advice; instead, all information, content, and materials contained within this message are for educational and/or consultative purposes only.*